Pseudosarcomatous (Proliferative) Fibroblastic Lesions

Benign and Intermediate Fibroblastic/Myofibroblastic Lesions

Proliferative Lesions Without Atypia

Cancer Control 321 determine the inherent risk they presented. Over 10,000 specimens were divided into three groups: nonproliferative lesions,proliferative lesions without atypia, and proliferative lesions with atypia. Their findings suggested a 1.9 times greater risk for proliferative lesions without atypia and 5.3 times greater risk for proliferative lesions with atypia.1,2 Subsequent case-co...

Proliferative Lesions and Neoplasia

I. Causative Agent and Disease Reports of abnormal proliferation of tissues in marine decapod crustaceans have been extremely rare. There have been less than a dozen cases in the literature of which only four have shown convincing evidence of cancer. Cancers or neoplasms are growths of abnormal cells that proliferate uncontrollably and have no useful function as opposed to cells that are normal...

Angiogenesis and lymphangiogenesis in parathyroid proliferative lesions.

Angiogenesis and lymphangiogenesis are involved in tumoral growth and metastatic spread. There is little information on angiogenesis and no available data on lymphangiogenesis in parathyroid glands (PTG). Using immunohistochemistry for CD34, LYVE-1 (specific markers for vascular and lymphatic endothelium, respectively), vascular endothelial growth factor (VEGF)-A, VEGF-C, and fibroblast growth ...

Endometrial proliferative lesions associated with uterine fibromatosis.

Hysteroscopy and uterine curettage are required in cases of atypical hyperplasia in premenopause and in all cases of hyperplasia with/without atypia in postmenopausal women. Biopsic curettage is the method of choice in the diagnosis of endometrial pathology. Transvaginal ultrasound and Doppler examination are useful in assessing the risk of endometrial hyperplasia or endometrial cancer in postm...